Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). - sprookjes - yvandenbroek - TriplyDB

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

http://www.wikidata.org/entity/Q36610166

about

Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Novel delivery strategies for glioblastoma Contemporary murine models in preclinical astrocytoma drug development Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.Tissue concentration of systemically administered antineoplastic agents in human brain tumors.Recurrent high-grade glioma: a diagnostic and therapeutic challenge.Molecular targeting of glioblastoma: Drug discovery and therapies Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux Experimental approaches for the treatment of malignant gliomas.A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.Treatment of glioblastoma multiforme using a combination of small interfering RNA targeting epidermal growth factor receptor and β-catenin.Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.Pathway inhibition: emerging molecular targets for treating glioblastoma.Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.Autophagy in brain tumors: a new target for therapeutic intervention.Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.Assessment of epidermal growth factor receptor status in glioblastomas.Combining molecular targeted agents with radiation therapy for malignant gliomas Molecularly targeted therapies for malignant gliomas.Present trend in the primary treatment of aggressive malignant glioma: glioblastoma multiforme.Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo.Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.Combination therapy for malignant glioma based on PTEN status.Targeting EGFR resistance networks in head and neck cancer.Treatment options for recurrent glioblastoma: pitfalls and future trends.Insights into pharmacotherapy of malignant glioma in adults.Nimotuzumab in pediatric glioma.Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02 Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.

P2860

Q21133610-8F88B259-156F-44C4-8A6C-92DFBF6F6E59 Q26822717-9A3DEF04-E072-4B9A-ACFD-9E9A18FBA60C Q27006099-A09CEA37-8EF8-44F6-9DF1-6A4557BAE84E Q27026937-B6F65066-5D0B-4058-9CDF-95C72427224F Q27853219-BD43F712-ABD6-4574-ACE7-A7FDB2BF0F36 Q28829017-4C99C02D-2135-4DD5-B3C1-C86046979D74 Q30361219-E2529DB5-3822-406A-8F3B-8B368464DF60 Q30456087-43483EDA-1296-49D6-B022-0627EF993945 Q33403967-4EC858DC-B0E3-40A8-B7C4-BDA97A0D3DA7 Q33427367-4641CC3C-EB33-4116-901C-F29B825AB440 Q33844823-5FE926BB-E753-47CB-B426-E550E593F7C3 Q33864058-0A471B52-1789-406B-A17E-C67349E31F06 Q33911283-D81EF202-A4CE-44AF-8A8E-5740EEDE87F9 Q34028148-64F7D2C6-AF3B-41EF-B419-7D4C0DAB0EEE Q34127138-C634411C-862B-43CE-84F5-A70F2BC0B37F Q34132643-CE12118C-11BA-46DA-943C-0723D2E5A79C Q34132781-66999CBE-8129-4F5E-8FE1-3BDCA2A8CB97 Q34132872-1B8A3778-B2B6-45CE-99CC-41AE9C86903C Q34205345-5CA7B5B5-F36D-4CFC-89B1-BAFA32577E1E Q34447846-CA2A55A8-7239-473B-BD5D-E34FD92BEFAE Q35021359-0BE87A4E-3957-424A-8481-47EEAB2C8986 Q35027024-0B82C82C-F680-462F-88CC-77BE5D049EB9 Q35154233-52123F85-5E05-483F-B044-F6BA4CCC0CEA Q35624780-1144B25D-D91B-4F76-AB54-2BED095ACEEE Q35788884-5472EC28-343E-44F3-95DA-50566CD67436 Q36032533-34CEC068-6304-4227-8EB4-6A3874EBE3D4 Q37052272-FFE130CA-FE1C-4660-89E4-1F1AB66D6174 Q37099594-4E2E332B-80E8-4BAB-A9FE-0A69518F2A38 Q37107374-72EB0423-0332-4B21-81F5-CC6B1F1F42EF Q37160479-02EC02A7-418F-4C54-AB21-FC827B4A453D Q37205309-7FDEE760-B174-40A6-8F61-08EB50374665 Q37269431-28279AE0-F108-4B30-8172-19A10316E099 Q37308322-47C0BC10-80E1-4F16-9071-D9A44A193624 Q37316986-9FAC6F14-7252-4B4A-9699-8492DFAB93F3 Q37405633-7E15722B-9D6F-47D0-9501-8BC1A5A095E0 Q37483971-0DDD1932-7125-43BA-B951-704D06FAF7CB Q37575528-BE620EEE-F859-45E8-B961-AEA08AC04FDE Q37630569-7569EB52-BC08-403F-988C-863EEF6241AF Q37641248-2463A45D-EE5F-4779-B52A-88D50562A18D Q37729676-75CCE26B-FD4C-4A91-845E-026F84B3007E

P2860

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

http://www.wikidata.org/entity/Q36610166

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Gefitinib in patients with pro ...... vo di Neuro-Oncologia (GICNO).

@ast

Gefitinib in patients with pro ...... vo di Neuro-Oncologia (GICNO).

@en

type

label

Gefitinib in patients with pro ...... vo di Neuro-Oncologia (GICNO).

@ast

Gefitinib in patients with pro ...... vo di Neuro-Oncologia (GICNO).

@en

prefLabel

Gefitinib in patients with pro ...... vo di Neuro-Oncologia (GICNO).

@ast

Gefitinib in patients with pro ...... vo di Neuro-Oncologia (GICNO).

@en

P1433

Q36610166-FE4514A1-73B5-40AD-B2D3-2991F7E4BB97

P1476

Q36610166-678E55BA-5A92-4571-AA67-CFC45015C821

P2093

Q36610166-05243DF2-3A4E-44FE-9309-361F875665B2

Q36610166-0CE1157E-48D3-4220-9527-163F9E317192

Q36610166-25D175EF-5152-4B08-A9F6-51B2F66C0782

Q36610166-4483502D-3D73-41E2-8FCB-D42244B8B28C

Q36610166-5DD386C1-3DF7-4AF9-98F4-7AC32CA8BDB7

Q36610166-688327D2-51A0-40D5-8725-4F8CAB5F9FC7

Q36610166-BED73F6C-A650-411A-9673-B146487CD0BF

Q36610166-DD8CD4D4-B272-4385-B79F-75D38D49B2CD

P2860

Q36610166-14F51C9C-FFD1-4953-A66A-00F6E476818A

Q36610166-2202BC5A-64EC-4BDC-AFF7-4660F916B9B9

Q36610166-2B437277-5741-43A7-ABB7-ECA86C51C466

Q36610166-2D12B5CA-B33B-4647-AC3A-0B6E55FA2871

Q36610166-45480428-DD63-49CF-B2C9-C90FF93A9A28

Q36610166-49FD1377-3FA3-4E9C-93C2-855A555CC850

Q36610166-4BA1BB79-20B7-4915-B1FC-13B202038709

Q36610166-4BE10FA1-BC9D-4270-914B-A688DFB9058E

Q36610166-82AEFD0F-2B5C-4C5F-9C14-8EDBFD31259A

Q36610166-8FD5E82D-C6D9-44AC-ACEC-19AF5A04F029

P2888

Q36610166-6C2E9307-22E6-4E92-9BBA-A16DF52E07F4

P304

Q36610166-A14CAAA4-1499-4F11-99BA-3390E3DDAD5F

P31

Q36610166-F6282781-6B4F-4152-ACCC-21333CD7887B

P356

Q36610166-272004AA-5448-4ED7-91DF-BC815BE3B600

P407

Q36610166-E68935F7-9A84-4BFA-ACB5-4A52524C87F6

P433

Q36610166-0E48325B-4D29-48B9-BBC8-566D222DBABE

P478

Q36610166-1253F81D-92B9-4415-8349-2EDED3EC6D16

P50

Q36610166-3E59807D-6D13-48D4-B1B9-1A95D4797534

Q36610166-78B11778-D5B1-4798-8F88-723EDBAA4BDD

Q36610166-89D445DF-CA9A-401B-BB8A-3688EF3E0EF5

Q36610166-DA7EF269-B98E-41DB-9247-11F05729A158

Q36610166-E020C45E-B86D-4AB0-881A-4F8C47F49BDA

P577

Q36610166-3FBF2898-515E-4408-9DE9-AFDF9C857FD3

P5875

Q36610166-77DBA4A8-8870-4EF5-B9B5-5ED55FDB0BE6

P698

Q36610166-10BFCA1F-2D7A-4E0D-96D2-39D780527439

P921

Q36610166-75D3567C-8932-4552-9811-C9B96D825E02

P932

Q36610166-8C729B67-012D-4668-A14C-884D4D615497

P356

P1433

British Journal of Cancer

P1476

Gefitinib in patients with pro ...... ivo di Neuro-Oncologia (GICNO)

@en

P2093

A Tosoni

http://www.w3.org/2001/XMLSchema#string

B Urbini

http://www.w3.org/2001/XMLSchema#string

D Grosso

http://www.w3.org/2001/XMLSchema#string

E Magrini

http://www.w3.org/2001/XMLSchema#string

G Cavallo

http://www.w3.org/2001/XMLSchema#string

L Crinò

http://www.w3.org/2001/XMLSchema#string

L Scopece

http://www.w3.org/2001/XMLSchema#string

V Blatt

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

P2888

P304

1047-1051

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6603669

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Tallini

Alba A. Brandes

Enrico Franceschi

P577

2007-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6453056

http://www.w3.org/2001/XMLSchema#string

P698

17353924

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

2360116

http://www.w3.org/2001/XMLSchema#string